Avalon Pharma to open its 4th new plant in Saudi Arabia in 2026
New production facility in Riyadh will create more than 100 jobs for Saudis
Avalon Pharma, the Saudi Arabia-based pharmaceuticals company, plans to open its fourth manufacturing plant, Avalon 4, in the industrial city of Riyadh.
Due to launch by 2026, Avalon 4 will produce complex medications such as oncology and general injectables, differentiating it from factories Avalon 1, 2 and 3, whose respective focuses are standard forms of prescription medications, health and personal care products and medical devices.
The new plant will create more than 100 jobs for Saudis, and the launch of more than 75 new products being manufactured in Saudi Arabia for the first time.
Brand portfolio
Founded in Saudi Arabia, the company owns a portfolio of 75 brands, ranging from healthcare products like Salinose, AvalonActiv, Avomeb and Ez-Clean to cosmetic and personal care products such as Alpha Plus, Avalon Care and EZ Care and extending to pharmaceutical drugs like Avogain, Avocom and Broncast.
Ahmad Al Tabbaa, Chair of the Board at Avalon Pharma, said: “Now in our 25th year serving Saudi Arabia, we consider ourselves to be one of the national champions of the Kingdom, positioned for growth and consistent investment within the sector as we demonstrate proof points of Vision 2030 in action.
“This new factory plant will allow Avalon Pharma to enter a new and elite segment of medicines like anticancer and other injectable products. And we look forward to its realisation over the next three years,” Al Tabbaa added.
Mohamed Maher Al Ghannam, Managing Director & CEO of Avalon Pharma, said: “As we are positioned at this point of growth and expansion for our company with Avalon 4, we look to both extend our influence, regionally and globally, in addition to continuing our deep investment towards our local customers.
“We look forward to achieving new heights with the addition of our fourth manufacturing plant as we continue this journey.”
Strong network
Avalon Pharma has commercial relationships with the leading chain pharmacies, high-street pharmacies, regional distributors, public and private hospitals, polyclinics, and leading hypermarket chains in Saudi Arabia.
The pharmaceuticals market in Saudi Arabia is valued at AED37.60 billion (SAR38.4 billion) and is expected to grow at a CAGR of 7.3% to reach AED66 billion (SAR67.4 billion) by 2030.
Featured image: Saudi Arabia has a fast-growing pharma production sector. Image: NCI
Last Updated on 10 months by Arnold Pinto
